At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADIL Adial Pharmaceuticals
Pre-Mkt 04-09 06:21:59 EDT
1.65
+0.01
+0.61%
盘前1.68
+0.03+1.82%
04:28 EDT
High1.79Low1.61Vol117.25K
Open1.70D1 Closing1.64Amplitude10.87%
Mkt Cap2.36MTradable Cap2.16MTotal Shares1.43M
T/O194.89KT/O Rate8.95%Tradable Shares1.31M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Adial commends bipartisan H.R. 7091 to expand veterans’ access to emerging AUD therapies
Reuters  ·  03-24
Adial commends bipartisan H.R. 7091 to expand veterans’ access to emerging AUD therapies
Adial Pharmaceuticals Q4 EPS $(11.48) Misses $(0.09) Estimate
Benzinga  ·  03-06
Adial Pharmaceuticals Q4 EPS $(11.48) Misses $(0.09) Estimate
Press Release: Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
Dow Jones  ·  03-06
Press Release: Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
Adial Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  03-06
Adial Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Adial Pharma posts FY 2025 net loss of USD 8.0 million, down 40%
Reuters  ·  03-06
Adial Pharma posts FY 2025 net loss of USD 8.0 million, down 40%
Adial Pharmaceuticals enters collaboration framework agreement with Molteni
TIPRANKS  ·  03-03
Adial Pharmaceuticals enters collaboration framework agreement with Molteni
Adial Pharmaceuticals Signs Exclusive AD04 Collaboration Framework With Molteni for Europe
Reuters  ·  03-03
Adial Pharmaceuticals Signs Exclusive AD04 Collaboration Framework With Molteni for Europe
Adial Pharmaceuticals Inc: Engaging With Potential Commercial Partners in United States, to Initiate Its Pivotal Phase 3 Program in Near Term
THOMSON REUTERS  ·  03-03
Adial Pharmaceuticals Inc: Engaging With Potential Commercial Partners in United States, to Initiate Its Pivotal Phase 3 Program in Near Term
Adial Pharmaceuticals Signs an Exclusive Ad04 Collaboration Framework With Molteni Farmaceutici for Europe Which Anticipates Nearly $60 Million in Potential Royalties and Milestones Upon Execution of a Definitive Agreement
THOMSON REUTERS  ·  03-03
Adial Pharmaceuticals Signs an Exclusive Ad04 Collaboration Framework With Molteni Farmaceutici for Europe Which Anticipates Nearly $60 Million in Potential Royalties and Milestones Upon Execution of a Definitive Agreement
EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million
Benzinga_recent_news  ·  03-03
EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million
Adial Pharmaceuticals Inc expected to post a loss of $2.15 a share - Earnings Preview
Reuters  ·  02-27
Adial Pharmaceuticals Inc expected to post a loss of $2.15 a share - Earnings Preview
BRIEF-Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement
Reuters  ·  02-24
BRIEF-Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement
Adial Pharmaceuticals Regains Nasdaq Minimum Bid Price Compliance
Reuters  ·  02-24
Adial Pharmaceuticals Regains Nasdaq Minimum Bid Price Compliance
Adial Pharmaceuticals Highlights FDA Shift Toward Single Pivotal Trial Backed by Confirmatory Evidence
Reuters  ·  02-23
Adial Pharmaceuticals Highlights FDA Shift Toward Single Pivotal Trial Backed by Confirmatory Evidence
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire  ·  02-17
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Adial Pharmaceuticals price target lowered to $8 from $37.50 at Maxim
TIPRANKS  ·  02-11
Adial Pharmaceuticals price target lowered to $8 from $37.50 at Maxim
Adial Pharmaceuticals trading halted, news pending
TIPRANKS  ·  02-06
Adial Pharmaceuticals trading halted, news pending
Why Is Adial Pharmaceuticals Stock (ADIL) Down Today?
TIPRANKS  ·  02-05
Why Is Adial Pharmaceuticals Stock (ADIL) Down Today?
Adial Pharmaceuticals Implements Reverse Stock Split to Regain Compliance
TIPRANKS  ·  02-05
Adial Pharmaceuticals Implements Reverse Stock Split to Regain Compliance
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
GlobeNewswire  ·  02-04
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

Introduction

Company Name.
Adial Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Issue price:
--